United Bioceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 27-06-2024
- Paid Up Capital ₹ 0.50 M
as on 27-06-2024
- Company Age 7 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.82 Cr
as on 27-06-2024
- Revenue 25.22%
(FY 2023)
- Profit 29.49%
(FY 2023)
- Ebitda 22.53%
(FY 2023)
- Net Worth 54.61%
(FY 2023)
- Total Assets 16.68%
(FY 2023)
About United Bioceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹3.82 Cr.
Deepak Juneja and Hukam Sharma serve as directors at the Company.
- CIN/LLPIN
U33100DL2017PTC325675
- Company No.
325675
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Nov 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
West Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at United Bioceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Deepak Juneja  | Director | 06-Nov-2017 | Current |
| Hukam Sharma | Director | 06-Nov-2017 | Current |
Financial Performance of United Bioceuticals.
United Bioceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 25.22% increase. The company also saw a substantial improvement in profitability, with a 29.49% increase in profit. The company's net worth Soared by an impressive increase of 54.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of United Bioceuticals?
In 2023, United Bioceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
United Pharmatech (India) Private LimitedActive 16 years 2 monthsDeepak Juneja and Hukam Sharma are mutual person
Charges (Loans)
₹38.21 M
₹0
Charges Breakdown by Lending Institutions
- Others : 3.50 Cr
- Hdfc Bank Limited : 0.32 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Dec 2020 | Hdfc Bank Limited | ₹3.21 M | Open |
| 14 Dec 2020 | Others | ₹3.50 Cr | Open |
How Many Employees Work at United Bioceuticals?
United Bioceuticals has a workforce of 27 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of United Bioceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped United Bioceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.